Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Provided herein are methods of making degradable, additive-blended polymeric materials using microwave radiation and catalysts. The methods can include incorporation of therapeutic materials into the polymeric materials. There also are provided polymeric materials made by the methods and medical devices comprising the polymeric materials made by the methods.

High strength biomedical materials and processes for making the same are disclosed. Included in the disclosure are nanoporous hydrophilic solids that can be extruded with a high aspect ratio to make high strength medical catheters and other devices with lubricious and biocompatible surfaces. Polymers may be entrapped in pores of materials to provide a durable modification of the materials.

Fouling on the surface of biomaterials and medical devices by proteins and microorganisms in the body severely hinders device functionality and drastically shortens lifetime. Currently, there is high demand for coatings that mitigate this biofouling. In this invention, the use of polyacrylamides has been explored in hydrogel coatings by building the largest library of acrylamide-based copolymer anti-biofouling hydrogels (>160 combinations) to date. A combinatorial approach was used, exploiting the ease of hydrogel synthesis to examine a high-throughput screening of platelet adhesion, precursor to thrombosis and a common culprit in biofouling. Applicability has been demonstrated of top-performing polyacrylamide-based hydrogel by (i) coating affinity-based electrochemical biosensors in vitro in a whole blood assay, and (ii) through coating an electrochemical aptamer-based device for real-time monitoring of analytes in an in vivo closed-loop system.

Fouling on the surface of biomaterials and medical devices by proteins and microorganisms in the body severely hinders device functionality and drastically shortens lifetime. Currently, there is high demand for coatings that mitigate this biofouling. In this invention, the use of polyacrylamides has been explored in hydrogel coatings by building the largest library of acrylamide-based copolymer anti-biofouling hydrogels (>160 combinations) to date. A combinatorial approach was used, exploiting the ease of hydrogel synthesis to examine a high-throughput screening of platelet adhesion, precursor to thrombosis and a common culprit in biofouling. Applicability has been demonstrated of top-performing polyacrylamide-based hydrogel by (i) coating affinity-based electrochemical biosensors in vitro in a whole blood assay, and (ii) through coating an electrochemical aptamer-based device for real-time monitoring of analytes in an in vivo closed-loop system.

The present invention is an inflatable balloon which is enclosed by an expandable cover which becomes increasingly porous/permeable during expansion. The balloon is coated or enclosed with a matrix which contains a pharmaceutically active agent. During expansion of the balloon, the pharmaceutically active agent is released or extruded through the expandable cover into a body cavity such as an artery or vein. The present invention also provides for a method of treating a disease or condition by delivering the inflatable balloon to a particular body cavity.

A first alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes an antioxidant selected from gallic acid or a derivative thereof. A second alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes carboxymethyl cellulose or a derivative or salt thereof. The use of the compositions for preventing or retarding degradation of a functional coating on a medical device from reactive species generated during exposure of radiation, and a wetting agent comprising the compositions, are also provided. The wetting agent prevents or retards the hydrolytic degradation of the coating during the intended shelf-life of the wetted coated product.

Urinary catheters and methods for preventing bacterial infections.

Urinary catheters and methods for preventing bacterial infections.

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.